← Evidence map

ArticleRespiratory research2026

Qingre Runzao oral liquid and its key compound ophiopogonin D inhibit CXCL9 and block CXCL9/CXCR3 axis to ameliorate asthma by suppressing RAS/ERK pathway.

Lingxue Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Qingre Runzao oral liquid and its key compound ophiopogonin D inhibit CXCL9 and block CXCL9/CXCR3 axis to ameliorate asthma by suppressing RAS/ERK pathway. | OpenQuestion